title: Lipoprotein changes in familial hypercholesterolemia after extracorporeal immunoadsorption of low density lipoproteins.
abstract: The effects of extracorporeal immunoadsorption of LDL on the lipoprotein metabolism in two patients with familial hypercholesterolemia are reported. The immunoadsorbent consisted of F(ab')2 fragments of sheep anti-LDL antibodies, which had been coupled to Sepharose CL 4B. Within a time period of 3 to 3.5 hours a mean reduction of the level of total cholesterol by 76 +/- 4 p. cent could be obtained. The level of LDL cholesterol was reduced by 78 +/- 4 p. cent and the level of apo. B by 84 +/- 5 p. cent. Both LDL and VLDL were bound to the immunoadsorbent, while HDL was predominantly lowered by the plasma-dilution, which was in the order of 20 p. cent. The same was true for other serum proteins, not related to LDL or VLDL. The relative distribution of the different lipoprotein classes was again reached 3 days after the treatment, the initial lipid and apolipoprotein levels two to three weeks after the treatment. In a long-term therapy consisting of 45 treatments with a mean interval of 18 days between two treatments a mean cholesterol lowering of 42 p. cent could be achieved. No adverse effects and no sensitization to be heterologous protein were observed.
authors.affiliation: Institute for Clinical and Experimental Research, University of Berne, Switzerland.
authors.forename: W F
authors.initials: WF
authors.lastname: Riesen
authors.forename: W
authors.initials: W
authors.lastname: Jaross
authors.forename: C
authors.initials: C
authors.lastname: Descoeudres
authors.forename: R
authors.initials: R
authors.lastname: Mordasini
authors.forename: F
authors.initials: F
authors.lastname: Koban
authors.forename: H
authors.initials: H
authors.lastname: Thulin
authors.forename: S
authors.initials: S
authors.lastname: Fisher
authors.forename: S
authors.initials: S
authors.lastname: Bergmann
mesh_terms: D000328:Adult; D000936:Antigen-Antibody Complex; D001053:Apolipoproteins / Q000097:blood; D001781:Blood Component Removal; D002784:Cholesterol / Q000097:blood; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D007164:Immunosorbents; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D000936:Antigen-Antibody Complex; D001053:Apolipoproteins; D007164:Immunosorbents; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D002784:Cholesterol